Palliative and Supportive Care for Patients with Advanced and Terminal Heart Failure

A Practical Guide to Heart Failure in Older People

Volumn , Issue , 2009, Pages 241-269

  Ward, Christopher ^a,b   Dunn, Francis G ^c   Jenkins, Shona M M ^c   Leiper, J Martin ^d  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Stobhill Hospital ^*  (United Kingdom)

^c STOBHILL HOSPITAL   (United Kingdom)

^d NHS TAYSIDE   (United Kingdom)

Author keywords

Cognitive impairment and Alzheimer's disease; Conventional drug withdrawal; Management implications of advanced heart failure; Palliative and supportive care strategies; Palliative care needs of heart failure patients; Palliative care strategies generic and adaptable to clinical situations; Social and financial problems; Strategies relevant to patients with advanced and terminal heart failure; Support in the community The Gold Standard Framework (GSF) and Advanced Care Planning (ACP); Terminal heart failure identifying dying patient and providing end of life care

Indexed keywords

EID: 84889979925     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470742945.ch14     Document Type: Chapter

References (58)

1. World Health Organization (2007) Palliative Care. http://www.who.int/cancer/palliative/en/(last accessed 19 April 2007).
2. Liverpool Care. Pathway for the Care of the Dying. www.lcp-mariecurie.org.uk.
3. The Gold Standard Framework website: http://www.goldstandardsframework.nhs.uk/.
4. NHS Modernisation Agency Coronary Heart Disease Collaborative (2004) Supportive and Palliative Care for Advanced Heart Failure, Department of Health, London.
5. Scottish Partnership for Palliative Care (2008) Living and Dying with Advanced Heart Failure: A Palliative Care Approach. Scottish Partnership for Palliative Care, Edinburgh.
6. Adams, K.F. Jr and Zannad, F. (1998) Clinical definition and epidemiology of advanced heart failure. American Heart Journal, 135 (6 Pt 2 Su), S204-S215.
7. The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine, 325 (5), 293-302.
8. Pfeffer, M.A., McMurray, J.J., Velazquez, E.J. et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine, 349 (20), 1893-1906.
9. Pfeffer, M.A., Swedberg, K., Granger, C.B. et al. (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 362 (9386), 759-766.
10. Pitt, B., Zannad, F., Remme, W.J. et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine, 341 (10), 709-717.
11. Tendera, M. and Ochala, A. (2001) Overview of the results of recent beta blocker trials. Current Opinion in Cardiology, 16 (3), 180-185.
12. Masoudi, F.A., Wolfe, P., Havranek, E.P. et al. (2005) Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes. Journal of the American College of Cardiology, 46 (6), 955-962.
13. Sacks, F.M., Pfeffer, M.A., Moye, L.A. et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine, 335 (14), 1001-1009.
14. Faris, R., Flather, M.D., Purcell, H. et al. (2006) Diuretics for heart failure. Cochrane Database of Systematic Reviews 1, CD003838.
15. The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. New England Journal of Medicine, 336 (8), 525-533.
16. Pappone, C. and Santinelli, V. (2004) The who, what, why, and how-to guide for circumferential pulmonary vein ablation. Journal of Cardiovascular Electrophysiology, 15 (10), 1226-1230.
17. Cleland, J.G., Daubert, J.C., Erdmann, E. et al. (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. New England Journal of Medicine, 352 (15), 1539-1549.
18. Bristow, M.R., Feldman, A.M. and Saxon, L.A. (2000) Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. Journal of Cardiac Failure, 6 (3), 276-285.
19. Mueller, P.S., Jenkins, S.M., Bramstedt, K.A. et al. (2008) Deactivating implanted cardiac devices in terminally ill patients: practices and attitudes. Pacing and Clinical Electrophysiology, 31 (5), 560-568.
20. Nordgren, L. and Sorensen, S. (2003) Symptoms experienced in the last six months of life in patients with end-stage heart failure. European Journal of Cardiovascular Nursing, 2 (3), 213-217.
21. Johnson, M.J. (2007) Management of end stage cardiac failure. Postgraduate Medical Journal, 83 (980), 395-401.
22. Moore, D.P., Weston, A.R., Hughes, J.M. et al. (1992) Effects of increased inspired oxygen concentrations on exercise performance in chronic heart failure. Lancet, 339 (8797), 850-853.
23. Restrick, L.J., Davies, S.W., Noone, L. et al. (1992) Ambulatory oxygen in chronic heart failure. Lancet, 340 (8829), 1192-1193.
24. Russell, S.D., Koshkarian, G.M., Medinger, A.E. et al. (1999) Lack of effect of increased inspired oxygen concentrations on maximal exercise capacity or ventilation in stable heart failure. American Journal of Cardiology, 84 (12), 1412-1416.
25. Booth, S., Wade, R., Johnson, M. et al. (2004) The use of oxygen in the palliation of breathlessness. A report of the expert working group of the Scientific Committee of the Association of Palliative Medicine. Respiratory Medicine, 98 (1), 66-77.
26. Lorenz, K.A., Lynn, J., Dy, S.M. et al. (2008) Evidence for improving palliative care at the end of life: a systematic review. Annals of Internal Medicine, 148 (2), 147-159.
27. Clark, A.L. and McDonagh, T. (1997) The origin of symptoms in chronic heart failure. Heart, 78 (5), 429-430.
28. Chua, T.P., Harrington, D., Ponikowski, P. et al. (1997) Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. Journal of the American College of Cardiology, 29 (1), 147-152.
29. Johnson, M.J., McDonagh, T.A., Harkness, A. et al. (2002) Morphine for the relief of breathlessness in patients with chronic heart failure-a pilot study. European Journal of Heart Failure, 4 (6), 753-756.
30. Farncombe, M. and Chater, S. (1993) Case studies outlining use of nebulized morphine for patients with end-stage chronic lung and cardiac disease. Journal of Pain and Symptom Management, 8 (4), 221-225.
31. Williams, S.G., Wright, D.J., Marshall, P. et al. (2003) Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart, 89 (9), 1085-1086.
32. Patel, I.H., Soni, P.P., Fukuda, E.K. et al. (1990) The pharmacokinetics of midazolam in patients with congestive heart failure. British Journal of Clinical Pharmacology, 29 (5), 565-569.
33. Gales, B.J. and Menard, S.M. (1995) Relationship between the administration of selected medications and falls in hospitalized elderly patients. Annals of Pharmacotherapy, 29 (4), 354-358.
34. Biberdorf, D.J., Steens, R., Millar, T.W. et al. (1993) Benzodiazepines in congestive heart failure. Sleep, 16 (6), 529-538.
35. Bernardi, L., Spadacini, G., Bellwon, J. et al. (1998) Effect of breathing rate on oxygen saturation and exercise performance in chronic heart failure. Lancet, 351 (9112), 1308-1311.
36. Nordgren, L. and Sorensen, S. (2003) Symptoms experienced in the last six months of life in patients with end-stage heart failure. European Journal of Cardiovascular Nursing, 2 (3), 213-217.
37. Ponikowski, P., Anker, S.D., Chua, T.P. et al. (1999) Oscillatory breathing patterns during wakefulness in patients with chronic heart failure: clinical implications and role of augmented peripheral chemosensitivity. Circulation, 100 (24), 2418-2424.
38. Catapano, G., Pedone, C., Nunziata, E. et al. (2008) Nutrient intake and serum cytokine pattern in elderly people with heart failure. European Journal of Heart Failure, 10 (4), 428-434.
39. Levenson, J.W., McCarthy, E.P., Lynn, J. et al. (2000) The last six months of life for patients with congestive heart failure. Journal of the American Geriatric Society, 48 (5 Suppl), S101-S109.
40. World Health Organization (1996) Cancer Pain Relief, 2nd edition, World Health Organization, Geneva.
41. Verma, A.K., da Silva, J.H. and Kuhl, D.R. (2004) Diuretic effects of subcutaneous furosemide in human volunteers: a randomized pilot study. Annals of Pharmacotherapy, 38 (4), 544-549.
42. Goenaga, M.A., Millet, M., Sanchez, E. et al. (2004) Subcutaneous furosemide. Annals of Pharmacotherapy, 38 (10), 1751.
43. McCarthy, M., Lay, M. and Addington-Hall, J. (1996) Dying from heart disease. Journal of the Royal College Physician of London, 30, 325-328.
44. Lynne, J., Teno, J.M., Phillips, R.S. et al. for the SUPPORT Group Members (1997) Perceptions by family members of the dying experience of older and seriously ill patients. Annals of Internal Medicine, 126 (2), 97-106.
45. Coronary Heart Disease Collaborative: Supportive and palliative care for advanced heart failure. www.modern.nhs.uk/chd.
46. National Institute for Clinical Excellence (NICE) (2004) Improving Supportive and Palliative Care for Adults with Cancer. Royal College of Physicians, London. Available at www.nice.org.uk.
47. British Medical Association (2007) Advance decisions and proxy decision-making in medical treatment and research, Guidance from the BMA's medical Ethics Department. British Medical Association, London.
48. McCarthy, M. and Addington-Hall, J. (1997) Communication and choice in dying from heart disease. Journal of the Royal Society of Medicine, 90, 128-131.
49. Boyd, K.J., Murray, S.A., Kendall, M. et al. (2004) Living with advanced heart failure: a prospective, community based study of patients and their carers. European Journal of Heart Failure, 6 (5), 585-591.
50. Kaye, P. (1996) Breaking Bad News: A Ten Step Approach, EPL Publications, 41 Park Avenue North, Northampton, NN3 2HT.
51. NHS End of Life Care Programme (2007) Department of Health, London. Available at www.endoflifecare.nhs.uk.
52. Kuter, J., Steiner, J., Corbett, K. et al. (1999) Information needs in terminal illness. Social Science and Medicine, 48, 1341-1352.
53. Thomas, C. and Morris, S. (2001) What are the Psychosocial Needs of Cancer Patients and their Main Carer? Institute of Health Research, Lancaster University.
54. Scottish Partnership for Palliative Care (2006) Joined Up Thinking-Joined Up Care. Scottish Partnership for Palliative Care, Edinburgh.
55. MERIT-HF study Group (1999) Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Cardiac Failure (MERIT-HF). Lancet, 353, 2001-2007.
56. British Heart Foundation (2007) Implantable cardioverter defibrillators in patients who are reaching the end of life A discussion document for health professionals. www.bhf.org.uk/publications.
57. Anderson, H., Ward, C. and Eardley, A. (2001) The concerns of patients under palliative care and a heart failure clinic are not being met. Palliative Medicine, 15 (4), 279-286.
58. Glare, P., Dickman, A. and Goodman, M. (2003) Symptom control in care of the dying, in Care of the Dying: A Pathway to Excellence (eds J. Ellershawe and S. Wilkinson), Oxford University Press, pp. 42-61.